secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2024-10-10T23:59:59+00:00
Accession:  0001193125-24-235598
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest inks Roche atezolizumab supply deal for Phase 3 liver cancer trial; extends rights plan
--------------------------------------------------------------------------------

- Master clinical supply agreement with Roche for free atezolizumab in planned Phase 3 trial of amezalpat (TPST-1120) in first-line unresectable/metastatic HCC.
- Phase 3 study: TPST-1120 + atezolizumab + bevacizumab vs placebo + atezolizumab + bevacizumab; Tempest retains all data from the trial.
- Board extended rights plan to expire after 2025 annual meeting or Oct 2026 if stockholders approve, citing stock undervaluation after positive survival data and FDA alignment.
- Rights plan triggers at 10% beneficial ownership (15% for passive institutions), with grandfathering for existing holders above threshold.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000119312524235598/0001193125-24-235598-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000119312524235598/d877681d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-235598

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer